Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.

Steven P Marso,Florian M M Baeres,Stephen C Bain,Bryan Goldman,Mansoor Husain,Michael A Nauck,Neil R Poulter,Richard E Pratley,Anne Bloch Thomsen,John B Buse

Journal of the American College of Cardiology（2020）

引用 56|浏览88

暂无评分

摘要

Based on these findings, liraglutide should be considered suitable for patients with T2D with or without a history of NYHA functional class I to III HF. (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER]; NCT01179048).

查看译文

关键词

heart failure,GLP-1 receptor agonist,liraglutide,major adverse cardiovascular events,mortality,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要